甲氨蝶呤联合他克莫司与甲氨蝶呤联合艾拉莫德治疗难治性类风湿关节炎的临床效果对比

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate and compare the clinical effects of Methotrexate(MTX)combined with Tacrolimus(TAC)or Ilalimide(IT)in the treatment of refractory rheumatoid arthritis(RRA).Methods A total of 92 patients with RRA admitted to our hospital from September 2015 to June 2018 were selected as the subjects,and randomly divided into observation group and control group,with 46 cases in each group.Patients in the control group were treated with MTX plus TAC,and patients in the observation group were given MTX plus IT.The clinical efficacy of the patients of the two groups,the joint pain index before and after treatment,the joint swelling index,the morning stiffness time and the VAS scores,and the incidence of adverse drug reactions were analyzed and compared.Results The total remission rate of the observation group was higher than that of the control group (P＜0.05).The postoperative pain index,joint swelling index and VAS scores of the observation group were lower than those of the control group,and morning stiffness time in the observation group was shorter than that in the control group (P＜0.05).There was no significant difference in the total incidence of complications between the two groups(P＞0.05).Conclusion MTX combined with IT in the treatment of RRA is superior to tacrolimus combined with TAC in improving patients′clinical symptoms and improving curative effect,and the safety of the two treatments is equivalent.

Key words： Tacrolimus Methotrexate Ilalimide Refractory rheumatoid arthritis Clinical controlled study

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I3/47

[1]	许相洋，张文州.类风湿关节炎的诊断及其药物治疗研究进展[J].中国医药导报，2016，13（30）：56-59.
[2]	兰瑛，胡蝶，宋海宁，等.甲氨蝶呤治疗类风湿关节炎有效性与安全性的系统评价[J].中国药房，2016，27（21）：2928-2933.
[3]	张咏赞，张翠欣.他克莫司药理作用及临床疗效的研究进展[J].中国医院药学杂志，2016，36（3）：241-244.
[4]	Lee JE，Kim IJ，Cho MS，et al.A case of rheumatoid vasculitis involving hepatic artery in early rheumatoid arthritis[J].J of Korean Med Sci，2017，32（7）：1207-1210.
[5]	孟岩，李明远，罗德梅，等.艾拉莫德片联合甲氨喋呤片治疗老年类风湿关节炎的临床研究[J].中国临床药理学杂志，2017，33（12）：1098-1101.
[6]	Lau CS，Chia F，Harrison A.APLAR rheumatoid arthritis treatment recommendations[J].Int J Rheum Dis，2015，18（7）：685-713.
[7]	吴逢波，孙闻续，黄媛，等.依那西普联合甲氨蝶呤与甲氨蝶呤单用比较治疗类风湿关节炎有效性和安全性的Meta 分析[J].四川医学，2016，37（10）：1144-1148.
[8]	甘雨舟，李茹.甲氨蝶呤治疗类风湿关节炎的跌宕历程[J].中华风湿病学杂志，2018，22（1）：34-35.
[9]	罗东萍，刘秀梅，傅自力，等.他克莫司联合甲氨蝶呤治疗难治性类风湿关节炎临床分析[J].中华风湿病学杂志，2017，21（3）：185-187.
[10]	罗东萍，刘秀梅，牛红青，等.他克莫司治疗难治性类风湿关节炎疗效观察[J].山西医药杂志，2016，45（7）：805-807.
[11]	陈坚，丁振华，熊俊慧.他克莫司与甲氨蝶呤联合治疗难治性类风湿关节炎效果观察[J].药物流行病学杂志，2018，27（3）：157-159，168.
[12]	孟德钎，潘文友，李鞠，等.甲氨蝶呤联合艾拉莫德治疗难治性类风湿关节炎的效果[J].中国医药导报，2016，13（3）：137-141.
[13]	张琼，刘锦华.艾拉莫德：治疗类风湿关节炎的一种新选择[J].实用医学杂志，2014，30（1）：160-161.
[14]	王振杰.甲氨蝶呤与艾拉莫德联合治疗难治性类风湿关节炎的疗效及安全性分析[J].中国现代药物应用，2016，10（23）：105-106.
[15]	李连菊，王京旭.艾拉莫德分别联合甲氨蝶呤和双醋瑞因对难治性类风湿关节炎患者相关指标的影响比较[J].中国药房，2017，28（6）：769-772.
[16]	孟德钎，潘文友，刘焱，等.艾拉莫德联合甲氨蝶呤对难治性类风湿关节炎患者血管新生相关细胞因子的影响[J].医药导报，2016，35（2）：148-151.